|
NLS Pharmaceutics AG (NLSP) DCF Valuation
CH | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
NLS Pharmaceutics AG (NLSP) Bundle
Looking to assess the intrinsic value of NLS Pharmaceutics AG? Our (NLSP) DCF Calculator integrates real-world data with extensive customization features, enabling you to refine forecasts and enhance your investment strategies.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -.4 | .0 | -11.9 | -15.5 | -11.8 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | 4.2 | 2.3 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -4.6 | -2.3 | -11.9 | -15.5 | -11.8 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | .2 | .1 | 5.4 | 8.9 | .9 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .1 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | .0 | -.1 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | 2.5 | 4.0 | 1.7 | 2.4 | 4.6 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -4.6 | -2.3 | -11.9 | -15.5 | -11.8 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | 2.0 | 1.6 | -14.2 | -14.8 | -9.6 | -4.6 | .0 | .0 | .0 | .0 |
| WACC, % | 5.47 | 5.47 | 5.47 | 5.47 | 5.47 | 5.47 | 5.47 | 5.47 | 5.47 | 5.47 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -4.4 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -4 | |||||||||
| Net Debt | 1 | |||||||||
| Equity Value | -5 | |||||||||
| Diluted Shares Outstanding, MM | 38 | |||||||||
| Equity Value Per Share | -0.13 |
What You Will Get
- Editable Excel Template: A fully customizable Excel-based DCF Calculator featuring pre-filled real NLS Pharmaceutics AG (NLSP) financials.
- Real-World Data: Historical data and forward-looking estimates (as highlighted in the yellow cells).
- Forecast Flexibility: Adjust forecast assumptions such as revenue growth, EBITDA %, and WACC.
- Automatic Calculations: Instantly observe the effect of your inputs on NLS Pharmaceutics AG (NLSP) valuation.
- Professional Tool: Designed for investors, CFOs, consultants, and financial analysts.
- User-Friendly Design: Organized for clarity and ease of use, complete with step-by-step instructions.
Key Features
- Comprehensive NLSP Data: Pre-loaded with NLS Pharmaceutics AG's historical financial metrics and future projections.
- Customizable Financial Inputs: Modify revenue growth rates, profit margins, discount rates, tax assumptions, and capital expenditures.
- Interactive Valuation Model: Automatic recalculation of Net Present Value (NPV) and intrinsic value based on your specified inputs.
- Multiple Scenario Analysis: Develop various forecasting scenarios to evaluate different valuation results.
- Intuitive User Interface: Designed for ease of use, catering to both industry professionals and newcomers.
How It Works
- Step 1: Download the Excel file for NLS Pharmaceutics AG (NLSP).
- Step 2: Review the pre-filled financial data and forecasts for NLS Pharmaceutics AG (NLSP).
- Step 3: Adjust key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model update in real-time as you modify assumptions.
- Step 5: Evaluate the outputs and leverage the results for your investment strategies.
Why Choose This Calculator?
- Accurate Data: Real NLS Pharmaceutics AG (NLSP) financials ensure reliable valuation results.
- Customizable: Adjust key parameters like growth rates, WACC, and tax rates to align with your projections.
- Time-Saving: Pre-built calculations save you from starting from scratch.
- Professional-Grade Tool: Tailored for investors, analysts, and consultants.
- User-Friendly: Intuitive layout and step-by-step instructions make it accessible for all users.
Who Should Use This Product?
- Individual Investors: Make informed decisions about buying or selling NLS Pharmaceutics AG (NLSP) stock.
- Financial Analysts: Streamline valuation processes with ready-to-use financial models for NLS Pharmaceutics AG (NLSP).
- Consultants: Deliver professional valuation insights on NLS Pharmaceutics AG (NLSP) to clients quickly and accurately.
- Business Owners: Understand how biotech companies like NLS Pharmaceutics AG (NLSP) are valued to guide your own strategy.
- Finance Students: Learn valuation techniques using real-world data and scenarios related to NLS Pharmaceutics AG (NLSP).
What the Template Contains
- Historical Data: Includes NLS Pharmaceutics AG’s (NLSP) past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate NLS Pharmaceutics AG’s (NLSP) intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of NLS Pharmaceutics AG’s (NLSP) financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.